Maravai LifeSciences
MRVI
6.98
-0.21
-2.92%
Maravai LifeSciences
US · MRVI
#3116 by market cap
Listed 2020
6.98
-0.21
-2.92%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 18 in the most recent period (2026/Q3).
- Total institutional ownership rose 3.6 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 103.13% +3.64pp
- Institutions
- 229 +18
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund51.02%
Hedge Fund29.96%
VC/PE Fund13.50%
Public Company3.56%
Individual/Insider3.55%
Private Company2.51%
Insurance Company1.54%
Sovereign Wealth Fund0.39%
Family Office/Trust0.43%
Government Pension Fund0.39%
Top holders as of 2026-06-30
GTCR LLC
13.50% · 20.15M sh
BlackRock
7.08% · 10.56M sh
Braidwell LP
5.83% · 8.70M sh
Millennium Management LLC
5.21% · 7.77M sh
12 West Capital Management LP
4.73% · 7.06M sh
FMR
4.62% · 6.89M sh
Vanguard Capital Management, LLC
3.52% · 5.25M sh
Ophir Asset Management Pty Ltd
3.23% · 4.83M sh
Renaissance Technologies Corp.
2.67% · 3.99M sh
Deutsche Asset & Wealth Management
2.89% · 4.30M sh
First Eagle Investment Management, LLC
2.20% · 3.28M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| GTCR LLC | -- | 13.50% |
| Bernd Brust | Chief Executive Officer | 0.59% |
| Peter Leddy | Former Executive Vice President | 0.46% |
| Kevin Herde | Former Chief Financial Officer | 0.41% |
| William Martin | Former Chief Executive Officer | 0.25% |
| Gregory Lucier | Independent Director | 0.18% |
| Christine Dolan | Executive VP & GM of Cygnus Technologies | 0.17% |
| Robert Eckert | Chairperson | 0.17% |
| Rebecca Buzzeo | Former Executive Vice President | 0.15% |
| Susannah Gray | Independent Director | 0.11% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-08 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $7.52 |
| 2026-10-29 | Rajesh Asorpota | EVP & Chief Financial Officer | Sale to Issuer | -5,466 | $8.46 |
| 2026-10-07 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $7.43 |
| 2026-09-29 | Rajesh Asorpota | EVP & Chief Financial Officer | Sale to Issuer | -5,465 | $7.65 |
| 2026-09-07 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $7.32 |
| 2026-08-30 | Rajesh Asorpota | EVP & Chief Financial Officer | Sale to Issuer | -5,465 | $7.68 |
| 2026-08-09 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $6.23 |
| 2026-07-29 | Rajesh Asorpota | EVP & Chief Financial Officer | Sale to Issuer | -5,465 | $6.59 |
| 2026-07-07 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $5.92 |
| 2026-06-29 | Rajesh Asorpota | EVP & Chief Financial Officer | Sale to Issuer | -65,584 | $6.39 |
| 2026-06-09 | Kurt Oreshack | General Counsel | Automatic Disposition | -50,000 | $5.06–5.10 |
| 2026-06-09 | Kurt Oreshack | General Counsel | Intent to Sell (Form 144) | -25,000 | $5.10 |
| 2026-06-08 | Gregory Lucier | Independent Director | Other Acquisition | +46,293 | -- |
| 2026-06-08 | Gregory Lucier | Independent Director | Other Disposition | -46,293 | -- |
| 2026-06-08 | Kurt Oreshack | General Counsel | Intent to Sell (Form 144) | -25,000 | $5.06 |
| 2026-06-07 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -351,001 | $5.02 |
| 2026-05-25 | John DeFord | Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Constantine Mihas | Non-Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Sean Cunningham | Non-Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Gregory Lucier | Independent Director | Other Acquisition | +46,293 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Maravai LifeSciences discussion 0 comments